{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-012222","form_type":"8-K","ticker":"OABI","cik":"0001846253","company_name":"OmniAb, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.976809+00:00","generated_at":"2026-06-04T12:01:10.769466+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OmniAb Q4 revenue $4.8M, net loss $14.1M; 77 partners, 32 programs in clinic; guides 2024 op ex flat","bullets":["Q4 2023 revenue $4.8M vs $35.3M in Q4 2022, primarily due to $25M milestone in prior year.","Full-year 2023 net loss $50.6M ($0.51/share) vs net loss $22.3M ($0.26) in 2022.","Operating cash flow $2.3M; cash and investments $87.0M at Dec 31, 2023.","2024 operating expense expected flat vs 2023; cash use expected to decline substantially in 2025.","10 new licenses signed in 2023, 6 new antibodies entered clinic; launched OmniDeep and Omni dAb platforms."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-012222","json":"https://secwatch.observer/filing/0001628280-24-012222.json","markdown":"https://secwatch.observer/filing/0001628280-24-012222.md","text":"https://secwatch.observer/filing/0001628280-24-012222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/0001628280-24-012222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/oabi-20240320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T12:01:10.769466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b258a7f29ec97ee6cfe39fefae0a4e56157301db","claim":"OmniAb, Inc. reported 12 months ended December 31, 2023 results: revenue $34.2 million, net income $50.6 million, EPS $0.51 per share.","evidence_excerpt":"or $0.14 per diluted share, compared with net income of $6.8 million, or $0.07 per share, for the same period in 2022. Full Year 2023 Financial Results Revenue for 2023 was $34.2 million, compared with $59.1 million for 2022, with the decrease primarily due to the recognition of TECVAYLI ® milestones of $10.0 million in 2023 compared with $25.0 million in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/0001628280-24-012222-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"12 months ended December 31, 2023"},{"label":"Revenue","value":"$34.2 million"},{"label":"Net income","value":"$50.6 million"},{"label":"EPS","value":"$0.51 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ec898205df0eac8226e3d2d68c118c4ddf7a7de7","claim":"OmniAb, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million, net income $14.1 million, EPS $0.14 per diluted share.","evidence_excerpt":"as we are now staffed and resourced to efficiently leverage the future growth of the business.” Fourth Quarter 2023 Financial Results Revenue for the fourth quarter of 2023 was $4.8 million, compared with $35.3 million for the same period in 2022, with the decrease primarily due to the recognition of a $25.0 million milestone payment in the prior-year period related","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/0001628280-24-012222-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Revenue","value":"$4.8 million"},{"label":"Net income","value":"$14.1 million"},{"label":"EPS","value":"$0.14 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}